(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) on Tuesday reported a rise in revenue for the fourth quarter, helped by increased revenue from the Precision Medicine segment and RLS third-party.
For the three-month period to December 31, 2025, the company posted revenue of $208 million, higher than $142 million in the same period last year.
Revenue from the Precision Medicine segment moved up to $161 million from $139 million a year ago. RLS third-party revenue stood at $45 million, compared with $00.00 million last year.
TLX was down by 1.03% at $7.68 in the pre-market trade on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
